Comparison of Brain Natriuretic Peptide (BNP) and NT-proBNP in Screening for Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis
- 15 July 2010
- journal article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 37 (10), 2064-2070
- https://doi.org/10.3899/jrheum.090997
Abstract
Objective.To compare the performance of brain natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) in screening for pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc).Methods.Between January 2008 and March 2009, outpatients referred to our unit and satisfying LeRoy criteria for SSc were assessed for PAH. Doppler echocardiography, BNP measurement, and NT-proBNP measurement were done concomitantly for a complete clinical, instrumental, and biochemical evaluation. Right-heart catheterization was carried out in cases of suspected PAH [estimated pulmonary arterial pressure (PAP) ≥ 36 mm Hg; diffusion capacity for carbon monoxide (DLCO) ≤ 50% of predicted value; 1-year DLCO decline ≥ 20% in absence of pulmonary fibrosis; unexplained dyspnea].Results.One hundred thirty-five patients were enrolled (124 women, 11 men; 96 limited SSc, 39 diffuse SSc); precapillary PAH was found in 20 patients (15 limited SSc, 5 diffuse SSc). The estimated PAP correlated with both BNP (R = 0.3; 95% CI 0.14–0.44) and NT-proBNP (R = 0.3, 95% CI 0.14–0.45). BNP [area under the curve (AUC) 0.74, 95% CI 0.59–0.89] was slightly superior to NT-proBNP (AUC 0.63, 95% CI 0.46–0.80) in identification of PAH, with diagnosis cutoff values of 64 pg/ml (sensitivity 60%, specificity 87%) and 239.4 pg/ml (sensitivity 45%, specificity 90%), respectively. BNP (log-transformed, p = 0.032) and creatinine (p = 0.049) were independent predictors of PAH, while NT-proBNP was not (p = 0.50).Conclusion.In our single-center study, the performance of BNP was slightly superior to that of NT-proBNP in PAH screening of patients with SSc, although normal levels of these markers do not exclude diagnosis. We observed that impaired renal function is associated with an increased risk of PAH in SSc. Further multicenter studies are needed to confirm our results (ClinicalTrials.gov ID NCT00617487).Keywords
This publication has 37 references indexed in Scilit:
- Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatmentInternal Medicine Journal, 2007
- Diagnosis of Pulmonary Arterial HypertensionClinics in Chest Medicine, 2007
- Changes in causes of death in systemic sclerosis, 1972-2002Annals Of The Rheumatic Diseases, 2007
- Serum N-Terminal Brain Natriuretic Peptide as a Prognostic Parameter in Patients With Pulmonary HypertensionSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2006
- Concurrent Oral 8 – Bone and Cartilage: Biology and Disease (including Young Investigator Award Winner) [OP61–OP68]Rheumatology, 2006
- Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung diseaseArthritis & Rheumatism, 2005
- Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter studyArthritis & Rheumatism, 2005
- N-terminal-pro-brain natriuretic peptide as a haemodynamic marker in idiopathic pulmonary arterial hypertensionEuropean Respiratory Journal, 2005
- Isolated pulmonary hypertension in sclerodermaInternal Medicine Journal, 2005
- Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approachAnnals Of The Rheumatic Diseases, 2003